Similarly, CXCL12/CXCR4 activation also increased MMP2/MMP9 and urokinase-type plasminogen activator expression by the Wnt/β-catenin pathway, enhancing cancer metastatic tendency [46]. This evidence concerns the gene CXCL12 and cancer.